Novavax sees weak Covid vaccine sales
Novavax to Move Forward With Covid-19-Flu Vaccine After FDA Lifts Clinical Hold -- Update
Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, Sanofi will have the sole right to use Novavax's existing Covid-19 vaccine in combination with its own flu vaccine.
Revenue: US$84.5m (down 55% from 3Q 2023). Net loss: US$121.3m (loss narrowed by 7.2% from 3Q 2023). US$0.76 loss per share ...
BofA lowered the firm’s price target on Novavax (NVAX) to $12 from $14 and keeps a Neutral rating on the shares. The company announced ...
The Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its ...
Novavax's (NVAX) stock was trading down more than 6% Tuesday afternoon after the company lowered its guidance for sales for ...
Analyst Alec Stranahan of Bank of America Securities reiterated a Hold rating on Novavax (NVAX – Research Report), reducing the price ...
Novavax reports Q3 2024 sales of $84.5 million, beating estimates, with a net loss of $121 million. EPS improves, FDA ...
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...
Drug maker Novavax Inc. (NVAX), while reporting narrower net loss in its third quarter, on Tuesday trimmed its fiscal 2024 forecast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback